Germany’s Bayer signed a deal to sell the company’s Dr. Scholl’s footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million.
Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
GlaxoSmithKline will not make a play for Pfizer’s consumer health business. The British pharma giant’s decision came one day after another potential buyer, Reckitt Benckiser Group, announced that it would not seek to buy the Pfizer business unit, which is valued between $15 and $20 billion.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to overhaul the company’s pharmaceutical division. Since assuming GSK’s helm, Walmsley has replaced about 50 of its top managers.
Nestle is buying Canadian vitamin maker Atrium Innovations for $2.3 billion, expanding its presence in consumer healthcare.
GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.
GlaxoSmithKline’s new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain’s biggest drugmaker. Emma Walmsley wants to boost the core pharmaceuticals division and also bulk up GSK’s big consumer healthcare operation, a twin-track strategy that could strain finances and has fueled fears for the dividend.
Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.
Pfizer Inc. announced that the company is reviewing strategic alternatives for its Consumer Healthcare business.